Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. ... As of the most recent quarter, Q3, it reported having around $1.9 billion in cash, equivalents, and short ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why.
The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
*Stock Advisor returns as of May 13, 2024. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals.
Science & Tech. Shopping. Sports
For premium support please call: 800-290-4726 more ways to reach us